This specific model, validated for both germ-free and specific pathogen-free conditions, could provide nuanced insights into how apixaban might interact with IL-1β-mediated inflammation pathways and whether it has a role in halting or reversing the progression of SCC and adenocarcinoma. The gene discussed is IL1B; the disease is adenocarcinoma.